{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cabotegravir+Injection", "query": { "intervention": "Cabotegravir Injection" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 56, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cabotegravir+Injection&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T22:34:08.158Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06451341", "title": "IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV" ], "interventions": [ { "name": "Acceptability of Intervention Measure (AIM)", "type": "BEHAVIORAL" }, { "name": "Intervention Appropriateness Measure (IAM)", "type": "BEHAVIORAL" }, { "name": "Feasibility of Intervention Measure (FIM)", "type": "BEHAVIORAL" }, { "name": "HIV Stigma Scale Questionnaire", "type": "BEHAVIORAL" }, { "name": "HIV Treatment Satisfaction Questionnaire status version (HIVTSQs12)", "type": "BEHAVIORAL" }, { "name": "HIV Treatment Satisfaction Questionnaire change version (HIVTSQc12)", "type": "BEHAVIORAL" }, { "name": "Needs and Barriers Assessment", "type": "BEHAVIORAL" }, { "name": "Pre-visit Outreach", "type": "BEHAVIORAL" }, { "name": "Qualitative interview - patient participants", "type": "BEHAVIORAL" }, { "name": "Staff education", "type": "BEHAVIORAL" }, { "name": "Staff Month 7 and 15 Survey - Staff Burden and Engagement", "type": "BEHAVIORAL" }, { "name": "Qualitative interview - staff", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 75, "start_date": "2024-07-01", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-08T22:34:08.158Z", "location_count": 4, "location_summary": "Harlan, Iowa • Shenandoah, Iowa • Grand Island, Nebraska + 1 more", "locations": [ { "city": "Harlan", "state": "Iowa" }, { "city": "Shenandoah", "state": "Iowa" }, { "city": "Grand Island", "state": "Nebraska" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06451341" }, { "nct_id": "NCT02951052", "title": "Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "Cabotegravir (CAB) tablet", "type": "DRUG" }, { "name": "Rilpivirine (RPV) tablet", "type": "DRUG" }, { "name": "Cabotegravir - Injectable Suspension (CAB LA)", "type": "DRUG" }, { "name": "Rilpivirine - Injectable Suspension (RPV LA)", "type": "DRUG" }, { "name": "2 NRTIs plus an INI, NNRTI, or PI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 618, "start_date": "2016-10-28", "completion_date": "2029-12-31", "has_results": true, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-09-08T22:34:08.158Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02951052" }, { "nct_id": "NCT07672717", "title": "Cabotegravir-Hormone PK/PD Interactions for HIV Prevention", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV", "Prophylaxis", "Injectable" ], "interventions": [ { "name": "Cabotegravir Injectable Suspension (CAB LA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 32, "start_date": "2026-07-07", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-08T22:34:08.158Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07672717" }, { "nct_id": "NCT04973254", "title": "Improving Treatment and Retention Adherence in Nontraditional Settings", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CAB-RPV LA", "type": "OTHER" }, { "name": "Standard treatment within an HIV clinic", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Boston Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2022-02-23", "completion_date": "2023-03-28", "has_results": true, "last_update_posted_date": "2025-01-15", "last_synced_at": "2026-09-08T22:34:08.158Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04973254" }, { "nct_id": "NCT01593046", "title": "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "GSK1265744 Oral", "type": "DRUG" }, { "name": "GSK1265744 LAP 800mg intramuscular injection", "type": "DRUG" }, { "name": "GSK1265744 LAP 200mg subcutaneous injection", "type": "DRUG" }, { "name": "GSK1265744 LAP 200mg intramuscular injection", "type": "DRUG" }, { "name": "GSK1265744 LAP 400mg intramuscular injection", "type": "DRUG" }, { "name": "TMC278 LA 1200mg intramuscular injection", "type": "DRUG" }, { "name": "TMC278 LA 600mg intramuscular injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 43, "start_date": "2012-05", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2014-02-10", "last_synced_at": "2026-09-08T22:34:08.158Z", "location_count": 2, "location_summary": "Daytona Beach, Florida • Overland Park, Kansas", "locations": [ { "city": "Daytona Beach", "state": "Florida" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01593046" }, { "nct_id": "NCT03739996", "title": "Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Oral Cabotegravir (CAB)", "type": "DRUG" }, { "name": "Nucleoside Reverse Transcriptase Inhibitors (NRTIs)", "type": "DRUG" }, { "name": "Long-Acting Injectable Cabotegravir (CAB LA)", "type": "DRUG" }, { "name": "VRC07-523LS", "type": "BIOLOGICAL" }, { "name": "Standard of Care (SOC) ART", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2019-12-31", "completion_date": "2024-04-29", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-09-08T22:34:08.158Z", "location_count": 17, "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03739996" }, { "nct_id": "NCT05917509", "title": "A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DTG/3TC", "type": "DRUG" }, { "name": "Cabotegravir (CAB) LA", "type": "DRUG" }, { "name": "Rilpivirine (RPV) LA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2023-07-06", "completion_date": "2026-04-20", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-09-08T22:34:08.158Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Bakersfield, California • Fort Lauderdale, Florida + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05917509" }, { "nct_id": "NCT03639311", "title": "Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CAB LA", "type": "DRUG" }, { "name": "RPV LA", "type": "DRUG" }, { "name": "RPV", "type": "DRUG" }, { "name": "DTG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2018-09-24", "completion_date": "2023-01-30", "has_results": true, "last_update_posted_date": "2024-06-11", "last_synced_at": "2026-09-08T22:34:08.158Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03639311" }, { "nct_id": "NCT01754116", "title": "A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "GSK1265744 30 mg oral", "type": "DRUG" }, { "name": "Midazolam 3 mg oral + GSK1265744 30mg oral", "type": "DRUG" }, { "name": "GSK1265744 400 mg (200 nm)", "type": "DRUG" }, { "name": "GSK1265744 400 mg (1 micro m)", "type": "DRUG" }, { "name": "GSK1265744 400 mg (5 micro m)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 43, "start_date": "2013-01", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2014-04-21", "last_synced_at": "2026-09-08T22:34:08.158Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01754116" }, { "nct_id": "NCT05096949", "title": "Implementing Cabenuva in Arkansas HIV Programs", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV-1-infection", "Medication Adherence", "Satisfaction, Patient" ], "interventions": [ { "name": "Home visit delivery strategy", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2022-03-07", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2024-09-03", "last_synced_at": "2026-09-08T22:34:08.158Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05096949" } ] }